Department of Colorectal and Anal Surgery, Clinical Center of Intestinal and Colorectal Diseases of Hubei Province, Key Laboratory of Intestinal & Colorectal Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, 430071, People's Republic of China.
Department of Colorectal and Anal Surgery, Clinical Center of Intestinal and Colorectal Diseases of Hubei Province, Key Laboratory of Intestinal & Colorectal Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, 430071, People's Republic of China.
Int J Surg. 2016 Aug;32:58-64. doi: 10.1016/j.ijsu.2016.06.039. Epub 2016 Jun 23.
The aim of this study was to assess the safety, efficacy and outcomes of TST STARR (Stapled Transanal Rectal Resection) plus to treat Obstructed Defecation Syndrome (ODS) at mid-term follow-up.
From April 2013 to September 2014, 50 cases (7 male patients) with ODS caused by rectocele and/or internal rectal prolapse were treated with the new TST STARR Plus. Clinical data from the 18 month mid-term follow up, including efficacy and constipations were recorded.
The average duration of surgery was 21 ± 4 min (range 12-35 min). The average postoperative hospital stay was 5 days (range 4-8 days). The pathological findings showed that the specimens contained full-thickness rectal tissue in all patients. The mean volume of resected specimen was 12.3 cm(3). Postoperative complications included five cases with transient faecal urgency that dissipated after 3 months; one patient suffered anastomotic bleeding on the sixth day after surgery, with successful haemostasis achieved through conservative therapy. The Wexner constipation score improved in patients affected by ODS from 13.96 ± 2.37 preoperatively to 7.00 ± 3.90, 7.28 ± 3.91, 8.10 ± 4.05 and 8.44 ± 4.08 at 3,6,12 and 18 months postoperatively, respectively, with all p < 0.05. Overall outcome was reported as ''excellent'' in 42% of patients, ''good'' in 36% of patients, ''adequate'' in 12% of patients, and ''poor'' in 10% of patients after 18 months of follow-up.
The TST STARR Plus is a simple, safe, and effective option for selected patients with ODS. Long-term prospective clinical studies are needed to validate the advantages of this emerging, novel procedure.
本研究旨在评估 TST STARR(吻合器经肛直肠切除术)加治疗梗阻性排便综合征(ODS)的安全性、疗效和结果。
从 2013 年 4 月至 2014 年 9 月,50 例(7 例男性)因直肠前突和/或直肠内脱垂引起 ODS 的患者接受了新的 TST STARR Plus 治疗。记录了 18 个月中期随访的临床数据,包括疗效和便秘情况。
手术平均持续时间为 21±4 分钟(范围 12-35 分钟)。平均术后住院时间为 5 天(范围 4-8 天)。病理结果显示所有患者的标本均包含全层直肠组织。切除标本的平均体积为 12.3cm³。术后并发症包括 5 例暂时性粪便急迫,3 个月后消失;1 例患者术后第 6 天发生吻合口出血,通过保守治疗成功止血。受 ODS 影响的患者的 Wexner 便秘评分从术前的 13.96±2.37 改善至术后 3、6、12 和 18 个月的 7.00±3.90、7.28±3.91、8.10±4.05 和 8.44±4.08,均为 p<0.05。在 18 个月的随访后,整体结果报告为 42%的患者为“优秀”,36%的患者为“良好”,12%的患者为“适当”,10%的患者为“差”。
TST STARR Plus 是治疗 ODS 患者的一种简单、安全、有效的选择。需要进行长期前瞻性临床研究来验证这种新兴的新手术的优势。